MBL77 CAN BE FUN FOR ANYONE

mutations, in whom rituximab seems to have little added value.59 Other genomic subgroups, like individuals with BIRC3mutations presented the fact that, as stated under, CLL therapy is based about the existence or absence of these mutations. The present consensus is that, besides clonal mutations, subclonal mutations which has a variant allelic freq